Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important

Surgery. 2011 Dec;150(6):1143-52. doi: 10.1016/j.surg.2011.09.028.

Abstract

Background: Controversy exists regarding the role and extent of operation for patients with multiple endocrine neoplasia type 1 (MEN1) and hypergastrinemia.

Methods: An institutional MEN1 database was reviewed to identify patients with evidence of hypergastrinemia. The relationship of extent of resection to achievement of eugastrinemia was evaluated.

Results: Operation was performed in 20 patients with MEN1 and hypergastrinemia with a median follow-up of 71 months. Duodenal gastrinomas were identified in 85% of patients who underwent duodenal evaluation. Nodal metastases were identified in 80%. Patients who underwent anatomic regional lymph node dissection (RLND) had a median of 16 nodes removed, vs 1 in patients who did not undergo a formal regional lymphadenectomy. Eugastrinemia was achieved in 12 patients (60%), and 8 (40%) had persistent hypergastrinemia. Compared with patients with persistent hypergastrinemia, patients rendered eugastrinemic more often underwent duodenal evaluation (11/12 vs 2/8; P = .01) and RLND (11/12 vs 3/8; P = .03); there was no relationship between pancreatic resection and achievement of eugastrinemia (P = .32).

Conclusion: For patients with MEN1-associated hypergastrinemia selected for operative treatment, a strategy including duodenal evaluation and anatomic regional lymphadenectomy is associated with long-term eugastrinemia. In contrast, the extent of pancreatic resection should be dictated by the extent and distribution of pancreatic neuroendocrine neoplasms, rather than by the presence of hypergastrinemia.

Publication types

  • Evaluation Study

MeSH terms

  • Abdomen
  • Adult
  • Duodenal Neoplasms / blood
  • Duodenal Neoplasms / diagnosis
  • Duodenal Neoplasms / surgery*
  • Female
  • Gastrinoma / blood
  • Gastrinoma / surgery*
  • Gastrins / blood*
  • Humans
  • Lymph Node Excision*
  • Male
  • Middle Aged
  • Multiple Endocrine Neoplasia Type 1 / blood
  • Multiple Endocrine Neoplasia Type 1 / surgery*
  • Pancreatectomy*
  • Pancreatic Neoplasms / blood
  • Pancreatic Neoplasms / surgery*
  • Pancreaticoduodenectomy
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Gastrins